Baxter International

Medela is a company dedicated to transforming scientific research into practical healthcare solutions that support the health of mothers and infants. Specializing in breast milk feeding and baby products, Medela focuses on understanding the anatomy of the lactating breast and infant sucking patterns to address early breastfeeding challenges. Their offerings include research-based products designed to facilitate breastfeeding, as well as healthcare solutions aimed at hospitals and clinical education. By prioritizing customer feedback and observational research, Medela fosters a commitment to nurturing health for generations.

NovaXS is developing an advanced smart needle-free drug delivery platform designed to enhance medication adherence and optimize treatment outcomes.

Medically Home Group, Inc. is a Boston-based company that specializes in providing a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on shifting medical care from traditional hospital settings to patients' homes, particularly for those with serious or complex illnesses such as heart failure, pneumonia, and respiratory infections. Medically Home's technology-enabled platform connects patients with caregivers, facilitating ongoing monitoring and communication. This system allows patients and their families to access a centralized medical command center, which offers on-demand acute medical care management, ensuring that necessary medical support is available in a more comfortable and familiar environment.

Walela is a medical device company focused on developing sensor technology to enhance fetal and maternal health outcomes. Founded in 2021 by James Balman and headquartered in Chicago, Illinois, the company specializes in measuring fetal heart rate and blood pH levels. This innovative technology provides expectant mothers and healthcare professionals with critical diagnostics for assessing fetal health, helping to reduce the likelihood of unnecessary cesarean sections. Through its advanced medical solutions, Walela aims to improve overall maternal and fetal care.

Hill-Rom is an American medical technology company based in Chicago that designs, manufactures and supplies hospital equipment and medical supplies for healthcare facilities. Its product portfolio includes hospital beds for high- and low-acuity settings, patient support and safe mobility solutions, noninvasive therapeutic products for acute and chronic conditions, medical equipment rentals, surgical products, patient monitoring, vision screening and diagnostics, healthcare furniture, surgical workflow and precision positioning, and information technology solutions.

Hospital IQ LLC is a company that specializes in developing cloud-based software aimed at enhancing operational efficiency within hospitals. Founded in 2013 and headquartered in Newton, Massachusetts, the company provides a predictive analytics platform that optimizes surgical schedules, inpatient capacity, operating room usage, and discharge processes. Its technology employs artificial intelligence, machine learning, and workflow automation to deliver actionable insights, enabling hospital administrators and clinical department heads to make informed decisions regarding resource allocation and patient flow. By partnering with leading healthcare institutions, such as Brigham and Women’s Hospital, Hospital IQ systematically improves utilization and throughput across hospital networks. The company's mission is to apply operations research principles to enhance hospital performance, ultimately improving patient access, clinical outcomes, and financial results.

Alvotech is a fully integrated biopharmaceutical company dedicated to the development and manufacture of high-quality biosimilar medicines. Founded in 2013 by Róbert Wessman in Reykjavík, the company aims to enhance patients' health and quality of life worldwide by increasing access to effective therapies for various ailments. Through its focus on biosimilars, Alvotech strives to provide proven treatments that address the needs of patients globally.

Medasense is a medical technology company based in Ramat Gan, Tel Aviv, Israel, specializing in pain monitoring solutions. Its flagship product, the PMD-200, utilizes a proprietary non-invasive sensor and artificial intelligence to objectively monitor and quantify a patient's pain response through the NOL index. This unique platform is particularly valuable in operating rooms and critical care settings, where patients are often unable to communicate their pain levels. By providing real-time insights into pain management, the PMD-200 aims to optimize pain control and reduce the risk of overmedication, supporting improved patient safety and outcomes. Medasense's technology also extends to cloud-based solutions for clinics and home care, tapping into a broader market potential. The PMD-200 is distributed in Europe through an exclusive partnership with Medtronic and has received marketing clearance in several regions, including Canada, Latin America, and Australia. Founded in 2008, Medasense continues to focus on enhancing pain management solutions for healthcare providers.

Ayogo Health Inc., established in 2008 and headquartered in Vancouver, Canada, specializes in developing digital health solutions that engage patients and improve adherence to treatment plans for chronic conditions. The company's core products include GoodLife, a customizable platform combining gamification, incentives, and social features, and Alternate Reality Games, which blend online and real-world elements for educational purposes. Ayogo serves clients such as insurers, healthcare providers, and pharmaceutical companies by applying behavioral psychology and social gaming principles to enhance patient outcomes. The company's collaborative approach involves meaningful engagement with patients, end-users, and clients throughout project development.

toSense, Inc. is a healthcare technology company based in San Diego, California, focused on developing innovative solutions for at-home monitoring of chronic illnesses. Incorporated in 2008 and previously known as Perminova, Inc., the company specializes in the CoVa Monitoring System, a body-worn sensor designed for patients with conditions such as congestive heart failure and chronic obstructive pulmonary disease. This device, resembling a necklace, measures vital signs including thoracic impedance, heart rate, and respiration rate, using disposable electrodes to ensure accurate monitoring. The collected data is transmitted via gateways to a web-based system, allowing healthcare professionals to review patient information and detect potential health issues earlier than traditional methods. toSense emphasizes the integration of its hardware and software solutions to address real-world medical challenges effectively. As of March 31, 2020, toSense operates as a subsidiary of Baxter International Inc.

Seprafilm is a mechanical bioresorbable adhesion barrier designed to be applied to adhesiogenic tissues prior to surgical closure. Its primary purpose is to reduce the incidence, extent, and severity of postoperative adhesions in patients undergoing abdominal or pelvic laparotomy. By serving as an adjunct in surgical procedures, Seprafilm aims to mitigate the risks associated with adhesions that can occur between the abdominal wall and underlying viscera, thereby enhancing surgical outcomes and patient recovery.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Prescient Surgical, Inc. is a medical device manufacturer focused on preventing surgical site infections. The company has developed CleanCision, a wound retraction and protection system that combines wound protection and irrigation to continuously clear harmful bacteria from surgical incisions. This innovative approach aims to enhance patient outcomes and reduce healthcare costs, particularly for patients undergoing high-risk abdominal gastrointestinal surgery. Established in 2012, Prescient Surgical is headquartered in San Carlos, California.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating dialysis solutions for patients and healthcare providers. The company has developed the Tablo system, a hemodialysis machine designed for both acute and chronic care settings. Tablo features a compact console with integrated water purification, on-demand dialysate production, and advanced connectivity capabilities, including wireless data and sensor-based automation. This design aims to simplify the complexities and costs associated with dialysis, making it suitable for use in hospitals, dialysis clinics, and home settings. Originally founded as Home Dialysis Plus, Ltd. in 2003, the company rebranded to Outset Medical, Inc. in January 2015.

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Bugworks Research Inc. is a biotechnology company focused on developing innovative antibiotics to combat antimicrobial resistance (AMR). Founded in 2014, the company operates from its headquarters in Saratoga, California, with additional offices in Adelaide, Australia, and Bengaluru, India. Bugworks specializes in creating a new class of antibiotic drugs designed to withstand drug resistance, offering products such as GYROX-1, an intravenous solution for critical care infections; GYROX-2, an oral treatment for various infections; and GYROX-3, specifically for cystic fibrosis patients. The company's research platform emphasizes broad-spectrum assets and leverages expertise in cancer biology and immunology to address the challenges posed by drug resistance in healthcare.

Claris Injectables Limited is a sterile injectables pharmaceutical company that operates as a wholly-owned subsidiary of Claris Lifesciences Limited. Based in Ahmedabad, India, Claris specializes in the manufacture and marketing of a diverse range of injectable products, primarily focusing on generic drugs used in the treatment of critical illnesses. Their product offerings span multiple therapeutic areas, including anesthesia, blood products, anti-infectives, critical care, and nephrology. Claris serves a broad customer base that includes government institutions, corporate hospitals, and nursing homes. The company emphasizes quality and innovation, utilizing various delivery systems such as bags, vials, and ampoules. Claris has established three manufacturing facilities that are compliant with regulatory standards from authorities including the US FDA and MHRA. The company's commitment to excellence has been recognized through multiple awards from industry organizations. With a trained workforce experienced across product development, regulatory affairs, manufacturing, and sales, Claris Injectables is well-positioned in the specialty injectables market.

Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

Medasense is a medical technology company based in Ramat Gan, Tel Aviv, Israel, specializing in pain monitoring solutions. Its flagship product, the PMD-200, utilizes a proprietary non-invasive sensor and artificial intelligence to objectively monitor and quantify a patient's pain response through the NOL index. This unique platform is particularly valuable in operating rooms and critical care settings, where patients are often unable to communicate their pain levels. By providing real-time insights into pain management, the PMD-200 aims to optimize pain control and reduce the risk of overmedication, supporting improved patient safety and outcomes. Medasense's technology also extends to cloud-based solutions for clinics and home care, tapping into a broader market potential. The PMD-200 is distributed in Europe through an exclusive partnership with Medtronic and has received marketing clearance in several regions, including Canada, Latin America, and Australia. Founded in 2008, Medasense continues to focus on enhancing pain management solutions for healthcare providers.

Opsonix is developing and commercializing a pathogen-extracting therapy that uses its proprietary pathogen-capture proteins to remove infectious microbes and the toxins they release from circulating blood, offering a new broad-spectrum approach to transform the treatment of blood-borne infectious diseases, including sepsis.

Founded in 2009, TVA Medical develops and manufactures catheter-based equipment for treating end-stage renal disease and peripheral vascular diseases. Its flagship product is the everlinQ endoAVF system, which creates an arterio-venous fistula using a minimally invasive, endovascular approach.

SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

True North Therapeutics is a biotechnology company based in South San Francisco, California, founded in 2013 as a spin-out of iPierian. The company focuses on developing therapies that target the classical pathway of the immune system's complement system to address rare diseases with high unmet clinical needs. Its lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway, aiming to treat conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-mediated rejection, bullous pemphigoid, and other rare diseases in hematologic, kidney transplant, dermatology, and neurological spaces. True North Therapeutics was acquired by Bioverativ Inc.

SuppreMol is a privately held biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is at the forefront of a novel approach aimed at treating these conditions by targeting their underlying causes rather than just alleviating symptoms. SuppreMol focuses on the development of soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to exert specific immunoregulatory effects. This innovative strategy positions the company as a significant player in the field of immunotherapy, with the potential to advance treatment options for patients suffering from a range of autoimmune disorders.

AesRx is a biopharmaceutical company focused on developing innovative therapies for orphan diseases. The company’s lead program, Aes-103, targets sickle cell disease, a genetic disorder characterized by the production of abnormal hemoglobin that results in deformed red blood cells. These deformed cells can obstruct blood vessels, leading to a range of serious health complications, including chronic hemolytic anemia, pain crises, stroke, and acute chest syndrome. AesRx is committed to providing effective medicinal treatments for patients afflicted by this debilitating condition, alongside its efforts in developing drugs for inflammatory diseases of the lower intestine.

True North Therapeutics is a biotechnology company based in South San Francisco, California, founded in 2013 as a spin-out of iPierian. The company focuses on developing therapies that target the classical pathway of the immune system's complement system to address rare diseases with high unmet clinical needs. Its lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway, aiming to treat conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, antibody-mediated rejection, bullous pemphigoid, and other rare diseases in hematologic, kidney transplant, dermatology, and neurological spaces. True North Therapeutics was acquired by Bioverativ Inc.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Chatham Therapeutics LLC operates in the biotechnology sector. The company was formerly known as VECTORRX INC. The company was incorporated in 2010 and is based in Chapel Hill, North Carolina.

Xenetic Biosciences, Inc. is a biopharmaceutical company headquartered in Framingham, Massachusetts, specializing in the development of innovative cancer therapies and drug delivery solutions. The company focuses on advancing its XCART platform, a personalized chimeric antigen receptor T cell technology designed to target patient-specific tumor neoantigens and treat B-cell lymphomas. Additionally, Xenetic is developing its DNase platform to enhance the efficacy of existing cancer treatments by targeting neutrophil extracellular traps, which are linked to cancer progression and treatment resistance. The company also has an investigational drug candidate, XBIO-101, aimed at treating progestin-resistant endometrial cancer. Through collaborations with major pharmaceutical organizations, Xenetic Biosciences leverages its proprietary PolyXen drug delivery technology to improve the performance of various drugs and vaccines across critical medical areas, including oncology.

Covagen is a biopharmaceutical company specializing in the development of bispecific therapeutics known as FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach allows Covagen to design therapeutics with unique architectures, enhancing their efficacy in treating inflammatory diseases and cancer. The company aims to explore novel biological pathways with each product candidate, with its lead FynomAb, COVA322, currently being developed for inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic collaborations, notably with Mitsubishi Tanabe, to advance its drug development initiatives. The company is supported by a diverse group of investors committed to its research and therapeutic programs.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

The URINFO 2000 fluid monitoring system is the only feasible solution for the accurate, real-time, and continuous monitoring of urine output. The product is based on FlowSense’s patented optical flow sensing technology. URINFO2000 has been used in the critical care setting to optimize fluid and electrolyte balance, treat acute kidney injury, and prevent renal failure.

Gambro is a global medical technology company specializing in the development, manufacturing, and supply of products and therapies for kidney and liver dialysis, as well as other extracorporeal treatments for chronic and acute patients. Founded in 1964, Gambro has been a pioneer in dialysis technology, which is critical for patients suffering from organ failure, particularly since kidney transplantation is often not a viable option due to donor shortages. The company innovates in various areas, including hemodialysis, peritoneal dialysis, renal intensive care, and hepatic care, providing solutions that enhance treatment quality and efficiency in clinics and intensive care units. With around 8,000 employees, Gambro operates 13 production facilities across multiple countries and has a presence in more than 90 countries worldwide, demonstrating its commitment to improving patient care through advanced medical technologies.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Founded in 2007, Zytoprotec is an Austrian biotechnology company specializing in developing innovative peritoneal dialysis fluids. Its flagship product, PD-protec, aims to improve kidney failure treatment by protecting cells and enhancing patient quality of life.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Gliknik Inc. is a biopharmaceutical company focused on developing therapies for patients with cancer and immune disorders. Founded in 2007 and based in Baltimore, Maryland, Gliknik's product portfolio includes GL-0817, aimed at preventing the recurrence of squamous cell carcinoma of the oral cavity, and GL-2045, which targets various autoimmune diseases such as immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and Myasthenia gravis. Additionally, the company develops GB-4542, an anti-CD20 monoclonal antibody therapy. Gliknik employs several innovative platforms, including an Immunomodulator Platform that utilizes off-the-shelf peptide drugs to enhance immune responses against cancer, the Stradomer Platform that creates drugs mimicking the efficacy of human intravenous immunoglobulin, and the Stradobody Platform, which produces compounds akin to monoclonal antibodies for tumor cell targeting. Through these initiatives, Gliknik aims to provide meaningful therapies that alleviate suffering for patients facing these challenging health conditions.

Synovis Life Technologies is a medical device company focused on developing innovative solutions for the surgical and interventional treatment of various diseases. The company specializes in implantable biomaterial devices and offers a range of products designed for microsurgery. Its surgical tools aim to reduce risks and facilitate critical procedures, enhancing the safety and effectiveness of surgical interventions. Through its dedication to advancing medical technology, Synovis Life Technologies contributes to improved patient outcomes in the healthcare sector.

Baxa Corporation is a privately held global company located in Englewood, Colorado. It specializes in the development and distribution of pharmaceutical delivery equipment designed for the preparation, handling, packaging, and administration of liquid medications. The company's medical device platform is utilized in hospitals, critical care units, and alternate-site pharmacies, enabling healthcare providers to administer medications safely and effectively. Baxa's focus is on enhancing the delivery of pharmaceuticals to improve patient care outcomes.

Prism Pharmaceuticals, Inc. is an acute care pharmaceutical company founded in 2004 and based in King of Prussia, Pennsylvania. The company specializes in the development and commercialization of cardiovascular injectable products in the United States. Its notable offerings include NEXTERONE, an injectable formulation of amiodarone designed for the treatment of arrhythmias, and PM103, an intravenous version of clopidogrel bisulfate. Through its innovative products, Prism Pharmaceuticals aims to address critical needs in cardiovascular care.

ApaTech Ltd. is an ortho-biologics company specializing in the production of synthetic bone repair materials. Founded in 2001 and headquartered in Elstree, United Kingdom, the company offers a range of products designed to enhance bone formation and facilitate surgical procedures. Its flagship product, Actifuse, is a synthetic bone graft that promotes the formation of new bone in graft and host structures, making it suitable for small void filling and spinal fusion applications. Additionally, ApaTech provides ApaPore, a porous hydroxyapatite grafting material used for cemented revision of failed total joint arthroplasties, spinal fusions, fracture fixations, and treatment of bone defects. The Actifuse MIS Bone Graft Delivery System allows for controlled delivery and precise placement of the graft during both open and minimally invasive surgeries. ApaTech distributes its products across various countries, including those in Europe, the Middle East, and Australia, and maintains operations in London, Foxborough, Massachusetts, and Berlin, Germany.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

Fusion Medical Technologies manufactures proprietary surgical hemostatic sealant products. It develops collagen gel-based products for use in controlling bleeding in a variety of surgeries.

Somatogen is a biotech company developing a genetically engineered blood substitute.

Caremark is a provider of integrated pharmacy health care services in the United States, focusing on both pharmacy services and retail operations. Its pharmacy services encompass a range of offerings, including pharmacy benefit management, plan design, formulary management, Medicare Part D services, and clinical support such as disease management. The retail segment features a wide array of products, including prescription and over-the-counter medications, beauty products, and convenience items, operating through a vast network of retail drugstores and specialty pharmacies. Caremark serves various clients, including employers, insurance companies, managed care organizations, and individual consumers through multiple brands. Established in 1892 and headquartered in Woonsocket, Rhode Island, Caremark conducts its business through subsidiaries, aiming to provide affordable medication solutions while facilitating access to essential health care services.